Publications
Below are the most recent publications from the Chemical Neuroscience Program. All other published works can be found here.
- Development of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization
- Selective Mu-Opioid Receptor Imaging Using 18F-Labeled Carfentanils
- Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms
- Neuroinflammation at the Gray-White Matter Interface in Active-Duty U.S. Special Operations Forces
- Laminar Fluid Ejection for Olfactory Drug Delivery: A Proof of Concept Study
- Neuroreceptor Mapping in 2024
- Neurochemical characterization of 5-HT2AR partial agonists with simultaneous PET-MRI
- Molecular Imaging Reveals Antineuroinflammatory Effects of HDAC6 Inhibition in Stroke Models
- The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice
- The Development and Evaluation of a Novel Highly Selective PET Radiotracer for Targeting BET BD1
- Speech motor impairment in ALS is associated with multiregional cortical thinning beyond primary motor cortex
- PET imaging assist investigation of HDAC6 expression change in MDD and evaluating antidepressant efficacy of a newly developed HDAC6 inhibitor
- Functional Characterization of an Arylsulfonamide-Based Small-Molecule Inhibitor of the NLRP3 Inflammasome
- Cervical Cancer Screening and Prevention Uptake in Females with Autism Spectrum Disorder
- Design, synthesis, and preclinical evaluation of 11C/18F-labeled inhibitors for RIPK1 PET imaging
- Novel multi-modal methodology to investigate placebo response in major depressive disorder
- Development and Evaluation of [11C]I-58: A Novel PET Radiotracer Targeting BRD4 BD2 for Advanced Epigenetic Imaging
- 18 kDa Translocator protein (TSPO) is upregulated in rat brain after peripheral nerve injury and downregulated by diroximel fumarate
- Toward AI-driven neuroepigenetic imaging biomarker for alcohol use disorder: A proof-of-concept study
- Development of a New Positron Emission Tomography Imaging Radioligand Targeting RIPK1 in the Brain and Characterization in Alzheimer's Disease